The government is engaging with the drug manufacturers to ramp up the production of an antifungal drug used for the treatment of mucormycosis, the Chemicals and Fertilizers Ministry said, as a rash of cases of rare black fungus infection have been reported among people either recovered or recovering from COVID-19. With a spike in the cases of COVID-19 in the country, doctors have been reporting a rare infection mucormycosis, also called as black fungus, among people recovered from COVID-19. The infection is caused by exposure to mucor mould and it affects the sinuses, the brain and the lungs and can be life-threatening.
Govt ramps up availability of drug to fight Mucormycosis
ANI
12 May 2021, 20:37 GMT+10
New Delhi [India], May 12 (ANI): Amid a sudden increase in demand observed in some states for Amphotericin B which is being prescribed by physicians to patients suffering from Mucormycosis, a post COVID complication, the Government of India is engaging with the manufacturers to ramp up production of the drug, said the Ministry of Chemicals and Fertilizers on Wednesday.
The ministry further stated that the supply position is expected to improve with extra imports of this drug and an increase in its production domestically.
After reviewing the stock position with the manufacturers/importers, and the demand pattern of Amphotericin B the Department of Pharma, had on May 11, 2021, allocated this drug amongst the States/UTs based on expected supply that will be available from May 10 to May 31, 2021, stated the ministry.
Govt ramps up availability of Amphotericin B to fight post COVID complication Mucormycosis ANI | Updated: May 12, 2021 15:35 IST
New Delhi [India], May 12 (ANI): Amid a sudden increase in demand observed in some states for Amphotericin B which is being prescribed by physicians to patients suffering from Mucormycosis, a post COVID complication, the Government of India is engaging with the manufacturers to ramp upproduction of the drug, said the Ministry of Chemicals and Fertilizers on Wednesday.
The ministry further stated that the supply position is expected to improve with extra imports of this drug and an increase in its production domestically.
After reviewing the stock position with the manufacturers/importers, and the demand pattern of Amphotericin B the Department of Pharma, had on May 11, 2021, allocated this drug amongst the States/UTs based on expected supply that will be available from May 10 to May 31, 2021, stated the ministry.
Post Covid-19 Complication: Union Government Takes Steps To Ramp Up Availability Of Amphotericin B To Fight Mucormycosis
by Swarajya Staff - May 12, 2021 10:11 AM
A Representative Image (Pic Via Twitter)
A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from Mucormycosis, a rare but dangerous fungal infection and a post Covid-19 complication.
Mucormycosis affects sinuses, brain, lungs and can be life-threatening in diabetic or severely immunocompromised individuals, such as cancer patients or people with HIV/AIDS.
The Government of India has therefore engaged multiple manufacturers to ramp up production of the drug. The supply position is expected to improve with extra imports of this drug and increase in its production domestically.
›Remdesivir production will be up from 38.80 lakh units/month to 74 lakh units/month by May: MHA
Remdesivir production will be up from 38.80 lakh units/month to 74 lakh units/month by May: MHA
SECTIONS
Remdesivir production will be up from 38.80 lakh units/month to 74 lakh units/month by May: MHAPTI
Last Updated: Apr 23, 2021, 09:30 PM IST
Share
Synopsis
Union Home Secretary Ajay Bhalla, in a letter to chief secretaries of all states and Union territories (UTs), also conveyed that there will be interim allocation and supply of the life-saving injection to the states/UTs from April 21 to April 30.
The supply of Remdesivir injection and imported drug Toclizumab is under severe constraint due to sharp increase in demand.